ALLR (Allarity Therapeutics) Insider Ownership: 8.47 % (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALLR Allarity Therapeutics Inc ALLR
26 GF Score
Price $1.38
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics Insider Ownership?

Allarity Therapeutics ALLR +0.37% 26 Insider Ownership is 8.47 % as of Aug. 14, 2026. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Allarity Therapeutics's insider ownership is 8.47%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Allarity Therapeutics's Institutional Ownership is 5.97%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Allarity Therapeutics's Float Percentage Of Total Shares Outstanding is 99.85%.

Allarity Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics Insider Ownership Chart

Allarity Therapeutics Historical Data

The historical data trend for Allarity Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 5.14 5.31 5.34 3.70 3.40 5.56 5.56 8.47 8.47 8.47
ALLR
26GF Score
Allarity Therapeutics Inc ALLR
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.47 % mean?
Allarity Therapeutics (ALLR) has a Insider Ownership of 8.47 % as of Aug. 14, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Allarity Therapeutics and its competitors.
Is Allarity Therapeutics' Insider Ownership too high?
Allarity Therapeutics' current Insider Ownership is 8.47 %. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' Insider Ownership compare to TVGN and LGVN?
Allarity Therapeutics' Insider Ownership of 8.47 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current Insider Ownership is 8.47 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current Insider Ownership of 8.47 %. The current Insider Ownership is 8.47 %. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current Insider Ownership is 8.47 % as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score

Get the complete analysis for ALLR

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price